Tonix rises on Medicare payer deal for fibromyalgia drug
Seeking Alpha ·
Tonix Pharmaceuticals ( TNXP ) said it secured a managed Medicare payer agreement for its fibromyalgia treatment TONMYA (cyclobenzaprine HCl sublingual tablets), expanding coverage to about 9 million Medicare beneficiaries and bringing its total pharmacy coverage to approximately 145 million lives, effective Jan. 1, 2027.
AI 시장 분석
Tonix Pharmaceuticals announced a Medicare coverage agreement for its fibromyalgia treatment, TONMYA. Effective January 1, 2027, the agreement adds 9 million Medicare beneficiaries, bringing the total coverage to 145 million. This is expected to signal positive growth for the company's revenue base and market share.
상승 영향
- Biotech — TONMYA's Medicare coverage has expanded by 9 million beneficiaries to a total of 145 million, providing a direct catalyst for stable revenue growth and increased market penetration.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 35% · Bearish (Short) 65%
445 participants
Related News
- Hike, hold, or cut? Why the S&P 500 thrives most when rates stay steady
- Trading, M&A top expected talking points for JPMorgan earnings, Kalshi shows
- Twin Vee PowerCats to merge with USFM subsidiary to privatize recreational marine business
- Meta Expands AI Data Center to 5GW, Raises Investment Above $50 Billion
- BofA downgrades Papa John’s to Underperform, cuts price target
- Chesapeake Utilities to build $1.2B Florida gas pipeline project